SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

In this study data of patients with moderate or severe acute exacerbations of chronic bronchitis (AECB) were collected. There were two different cohorts which were compared (Moxifloxacin and other antibiotics) concerning effectiveness and tolerance. It was a prospective study which was accomplished in 100 ambulatory practice offices.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Bronchitis Bronchial Diseases Bronchitis Bronchitis, Chronic Chronic Disease Disease Attributes Disease Progression Infections Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases Respiratory Tract Infections

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Many Locations, Germany

About this study

The study design was slightly changed to adapt the target population. Due to these changes the study was restarted on 8th December 2009.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Acute exacerbation of chronic bronchitis from Anthonisen type I or II
FEV1 of < 50 %
Patient must be ensured in the statutory health insurance
Further contraindications of the prescribed pharmaceutical products must be considered

Exclusion criteria

Patients who change from one cohort to the other

Treatment and study plan

Moxifloxacin (Avelox, BAY12-8039)

Drug

Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information

Primary outcomes

Effectiveness and tolerance of/to the different therapies

Time frame: within the first 14 days
Possible hospitalisation rate

Time frame: within the first 14 days

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Registry information

Official study title

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe AECB

Acronym: SYMPROVE III

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Apr 9, 2009
Registry last updated: Jun 23, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed